Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Corpay
CPAY
|
+$50.4M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$40.6M |
| 3 |
Centene
CNC
|
+$33.7M |
| 4 |
Clarivate
CLVT
|
+$27.5M |
| 5 |
Baxter International
BAX
|
+$23.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$35.3M |
| 2 |
Salesforce
CRM
|
+$28.3M |
| 3 |
Flex
FLEX
|
+$21.2M |
| 4 |
IPG Photonics
IPGP
|
+$18.1M |
| 5 |
Lyft
LYFT
|
+$17.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.43% |
| 2 | Healthcare | 14.56% |
| 3 | Communication Services | 14.3% |
| 4 | Consumer Discretionary | 11.94% |
| 5 | Industrials | 8.06% |
Similar funds
Invenomic Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Invenomic Capital Management held 186 positions worth $1.77B, up 20% from $1.47B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Invenomic Capital Management deployed $195M of net new capital in Q1 2023, opening 46 new positions and adding to 63 existing holdings. Its largest new stake was Corpay: 248,424 shares worth $52.4M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Applovin, an estimated $35.3M trimmed.
- Invenomic Capital Management's largest Q1 2023 buy was Corpay: 248,424 shares worth $52.4M.
- Invenomic Capital Management added most to Centene in Q1 2023, an estimated $33.7M increase.
- Invenomic Capital Management's biggest Q1 2023 reduction was Applovin, cutting an estimated $35.3M.
- Invenomic Capital Management fully exited Salesforce in Q1 2023, selling an estimated $28.3M.
- Invenomic Capital Management's ten largest holdings make up 26% of its $1.77B portfolio in Q1 2023.
- Invenomic Capital Management opened 46 new positions and closed 46 in Q1 2023.
- Invenomic Capital Management's portfolio value rose 20% quarter-over-quarter to $1.77B.
Based on Invenomic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.